Breast - British Journal of Surgery

A 34-year-old woman who was breastfeeding presented with 2 weeks of worsening left breast pain, swelling and erythema. What is the complication to be aware of during and after incision and drainage?

View

Scientific Surgery

Implant based breast reconstruction with acellular dermal matrix safety data from an open-label, multicenter, randomized, controlled trial in the setting of breast cancer treatment. Ann Surg 2019; 269: 836-841.

Authors: Lohmander F, Lagergren J, Roy P, Johansson H, Brandberg Y, Eriksen C et al.

Scientific Surgery

Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.

Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.

Scientific Surgery

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452.

Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Scientific Surgery

Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-628.

Authors: Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al.

Scientific Surgery

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1385-1393.

Authors: Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M et al.

Scientific Surgery

Quality of life and patient satisfaction after one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast reconstruction (BRIOS): primary outcome of a randomised, controlled trial. Lancet Oncol 2018; 19: 1205-1214.

Authors: Negenborn VL, Yooung-Afat DA, Dikmans REG, Smit JM, Winters HAF, Don Griot JPW et al.

Scientific Surgery

Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol 2018; 36: 3126-3133.

Authors: Bardia A, Parton M, Kummel S, Estevez LG, Huang C-S, Cortes J et al.

Scientific Surgery

Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node–positive and high-risk lymph node–negative breast cancer (E5103). J Clin Oncol 2018; 36: 2621-2629.

Authors: Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA et al.

Scientific Surgery

Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor–treated patients: CCTG MA.27. J Natl Cancer Inst 2018; 110: 1003–1008.

Authors: Strasser-Weippl K, Higgins MJ, Chapman J-AW, Ingle JN, Sledge GW, Budd GT et al.

Scientific Surgery

Prospective randomized trial of use of in-house prepared low-cost radiopharmaceutical versus commercial radiopharmaceutical for sentinel lymph node biopsy in patients with early stage invasive breast cancer. World J Surg 2018; 42: 1391-1395.

Authors: Agarwal G, Rajan S, Mayilvaganan S, Mishra A, Krishnani N, Gambhir S et al.

Scientific Surgery

Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122-137.

Authors: Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I et al.

Older Entries

Newer Entries